A 40-year-old male presented with a 6-month history of a gradually progressing, painless, firm, 10 × 8 mm erythematous nodule on his nose \[[Figure 1](#F1){ref-type="fig"}\]. Skin biopsy showed nodular deposition of eosinophilic, acellular, amyloid material in the entire dermis, which was surrounded by focal plasma cell infiltrate \[[Figure 2](#F2){ref-type="fig"}\]. This material was congophilic \[[Figure 3](#F3){ref-type="fig"}\] and demonstrated kappa light chain restriction on immunohistochemistry \[[Figure 4](#F4){ref-type="fig"}\]. Systemic amyloidosis was ruled out by laboratory investigations, and thus, a diagnosis of primary nodular cutaneous amyloidosis, immunoglobulin light chain (AL) type was made.

![Firm, erythematous-yellow, 10 × 8 mm nodule on the nose](IDOJ-8-302-g001){#F1}

![Skin biopsy showing deposition of pale, pink, eosinophilic amyloid material in the dermis (H and E, ×200)](IDOJ-8-302-g002){#F2}

![The amyloid material shows congophilia (Congo red, ×200)](IDOJ-8-302-g003){#F3}

![The amyloid shows kappa light chain positivity (immunohistochemistry, ×200)](IDOJ-8-302-g004){#F4}

Cutaneous amyloidosis comprises three varieties -- macular, lichenoid, or the rare nodular form. The amyloid protein in the nodular form is of AL type, which consists of monoclonal immunoglobulin light chain.\[[@ref1][@ref2]\] It is thought that AL amyloid in the cutaneous nodular form is produced by local plasma cells infiltrating the dermis. Some authors have reported a 7--50% risk of progression from localized nodular cutaneous amyloidosis to systemic forms on long-term follow-up.\[[@ref3][@ref4]\] This patient did not reveal any clinical or laboratory manifestation of multiple myeloma during a 2-year follow-up. Consequently, it is important to exclude underlying systemic disease at presentation in such patients and long-term follow up is recommended.
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